Patents by Inventor Tana Omokoko

Tana Omokoko has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIGEN-SPECIFIC T CELL RECEPTORS AND T CELL EPITOPES
    Publication number: 20230405046
    Abstract: The present invention relates to the provision of clinically relevant T cell receptors and T cell epitopes which are useful for immunotherapy. The present invention also relates to therapies involving immune effector cells such as T cells expressing a T cell receptor disclosed herein and/or being specific for a T cell epitope disclosed herein.
    Type: Application
    Filed: March 15, 2021
    Publication date: December 21, 2023
    Inventors: Ugur SAHIN, Petra OEHM, Tana OMOKOKO, Andrea BREITKREUZ, Claudia TOLLIVER, Janina Patricia CASPAR, Lisa HEBICH, Anke OELBERMANN, Bettina STEEGE, Evelyna DERHOVANESSIAN, Sebastian NEWRZELA, Rene ROTH
  • CLAUDIN-18.2-SPECIFIC IMMUNORECEPTORS AND T CELL EPITOPES
    Publication number: 20230303656
    Abstract: The present invention provides Claudin-18.2-specific immunoreceptors (T cell receptors and artificial T cell receptors (chimeric antigen receptors; CARs)) and T cell epitopes which are useful for immunotherapy.
    Type: Application
    Filed: June 13, 2023
    Publication date: September 28, 2023
    Inventors: Ugur Sahin, Ozlem Tureci, Petra Oehm, Tana Omokoko, Andrea Breitkreuz, Karolina Anna Mroz, Lisa Hebich
  • Claudin-18.2-specific immunoreceptors and T cell epitopes
    Patent number: 11713346
    Abstract: The present invention provides Claudin-18.2-specific immunoreceptors (T cell receptors and artificial T cell receptors (chimeric antigen receptors; CARs)) and T cell epitopes which are useful for immunotherapy.
    Type: Grant
    Filed: May 9, 2016
    Date of Patent: August 1, 2023
    Assignees: BioNTech Cell & Gene Therapies GmbH, TRON—Translationale Onkologie An Der Universitätsmedizin der Johannes Gutenberg-Universität Mainz Gemeinnützige GmbH
    Inventors: Ugur Sahin, Ozlem Tureci, Petra Oehm, Tana Omokoko, Andrea Breitkreuz, Karolina Anna Mroz, Lisa Hebich
  • CLAUDIN-6-SPECIFIC IMMUNORECEPTORS AND T CELL EPITOPES
    Publication number: 20220306711
    Abstract: The present invention provides Claudin-6-specific immunoreceptors (T cell receptors and artificial T cell receptors (chimeric antigen receptors; CARs)) and T cell epitopes which are useful for immunotherapy.
    Type: Application
    Filed: April 4, 2022
    Publication date: September 29, 2022
    Inventors: Ugur SAHIN, Özlem TÜRECI, Petra SIMON, Tana OMOKOKO, Holger HOFF, Ralf-Holger VOSS, Andrea BREITKREUZ, Kathleen HOBOHM, Karolina Anna MROZ
  • ANTIGEN-SPECIFIC T CELL RECEPTORS AND T CELL EPITOPES
    Publication number: 20220288180
    Abstract: The present invention relates to efficient methods for providing antigen-specific lymphoid cells. These lymphoid cells may be used to provide antigen specific T cell receptors having a defined MHC restriction and to identify immunologically relevant T cell epitopes. Furthermore, the present invention relates to antigen-specific T cell receptors and T cell epitopes and their use in immunotherapy.
    Type: Application
    Filed: February 24, 2022
    Publication date: September 15, 2022
    Inventors: Ugur Sahin, Ozlem Tureci, Petra Simon, Tana Omokoko
  • INDIVIDUALIZED VACCINES FOR CANCER
    Publication number: 20220282322
    Abstract: The present invention relates to the provision of vaccines which are specific for a patient's tumor and are potentially useful for immunotherapy of the primary tumor as well as tumor metastases. In one aspect, the present invention relates to a method for providing an individualized cancer vaccine comprising the steps: (a) identifying cancer specific somatic mutations in a tumor specimen of a cancer patient to provide a cancer mutation signature of the patient; and (b) providing a vaccine featuring the cancer mutation signature obtained in step (a). In a further aspect, the present invention relates to vaccines which are obtainable by said method.
    Type: Application
    Filed: January 14, 2022
    Publication date: September 8, 2022
    Inventors: Ugur Sahin, Sebastian Kreiter, Mustafa Diken, Jan Diekmann, Michael Koslowski, Cedrik Britten, John Christopher Castle, Martin Löwer, Bernhard Renard, Tana Omokoko, Johannes Hendrikus De Graaf
  • Claudin-6-specific immunoreceptors and t cell epitopes
    Patent number: 11345731
    Abstract: The present invention provides Claudin-6-specific immunoreceptors (T cell receptors and artificial T cell receptors (chimeric antigen receptors; CARs)) and T cell epitopes which are useful for immunotherapy.
    Type: Grant
    Filed: June 18, 2019
    Date of Patent: May 31, 2022
    Assignees: BioNTech Cell & Gene Therapies GmbH, TRON-Translationale Onkologie An Der Universitatsmedzin Der Johannes Gutenberg-Universitat Mainz, Ganymed Pharmaceuticals AG
    Inventors: Ugur Sahin, Özlem Türeci, Petra Simon, Tana Omokoko, Holger Hoff, Ralf-Holger Voss, Andrea Breitkreuz, Kathleen Hobohm, Karolina Anna Mroz
  • Antigen-specific T cell receptors and T cell epitopes
    Patent number: 11311611
    Abstract: The present invention relates to efficient methods for providing antigen-specific lymphoid cells. These lymphoid cells may be used to provide antigen specific T cell receptors having a defined MHC restriction and to identify immunologically relevant T cell epitopes. Furthermore, the present invention relates to antigen-specific T cell receptors and T cell epitopes and their use in immunotherapy.
    Type: Grant
    Filed: September 4, 2018
    Date of Patent: April 26, 2022
    Assignees: BioNTech Cell & Gene Therapies GmbH, Translationale Onkologie an der Universitätsmedizin der Johannes Gutenbera-Universität Mainz Gemeinnützine GmbH
    Inventors: Ugur Sahin, Ozlem Tureci, Petra Simon, Tana Omokoko
  • Individualized vaccines for cancer
    Patent number: 11248264
    Abstract: The present invention relates to the provision of vaccines which are specific for a patient's tumor and are potentially useful for immunotherapy of the primary tumor as well as tumor metastases. In one aspect, the present invention relates to a method for providing an individualized cancer vaccine comprising the steps: (a) identifying cancer specific somatic mutations in a tumor specimen of a cancer patient to provide a cancer mutation signature of the patient; and (b) providing a vaccine featuring the cancer mutation signature obtained in step (a). In a further aspect, the present invention relates to vaccines which are obtainable by said method.
    Type: Grant
    Filed: July 2, 2020
    Date of Patent: February 15, 2022
    Assignees: TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gGmbH, BioNTech SE
    Inventors: Ugur Sahin, Sebastian Kreiter, Mustafa Diken, Jan Diekmann, Michael Koslowski, Cedrik Britten, John Christopher Castle, Martin Löwer, Bernhard Renard, Tana Omokoko, Johannes Hendrikus De Graaf
  • INDIVIDUALIZED VACCINES FOR CANCER
    Publication number: 20210164034
    Abstract: The present invention relates to the provision of vaccines which are specific for a patient's tumor and are potentially useful for immunotherapy of the primary tumor as well as tumor metastases. In one aspect, the present invention relates to a method for providing an individualized cancer vaccine comprising the steps: (a) identifying cancer specific somatic mutations in a tumor specimen of a cancer patient to provide a cancer mutation signature of the patient; and (b) providing a vaccine featuring the cancer mutation signature obtained in step (a). In a further aspect, the present invention relates to vaccines which are obtainable by said method.
    Type: Application
    Filed: July 2, 2020
    Publication date: June 3, 2021
    Inventors: Ugur Sahin, Sebastian Kreiter, Mustafa Diken, Jan Diekmann, Michael Koslowski, Cedrik Britten, John Christopher Castle, Martin Lower, Bernhard Renard, Tana Omokoko, Johannes Hendrikus De Graaf
  • Individualized vaccines for cancer
    Patent number: 10738355
    Abstract: The present invention relates to the provision of vaccines which are specific for a patient's tumor and are potentially useful for immunotherapy of the primary tumor as well as tumor metastases. In one aspect, the present invention relates to a method for providing an individualized cancer vaccine comprising the steps: (a) identifying cancer specific somatic mutations in a tumor specimen of a cancer patient to provide a cancer mutation signature of the patient; and (b) providing a vaccine featuring the cancer mutation signature obtained in step (a). In a further aspect, the present invention relates to vaccines which are obtainable by said method.
    Type: Grant
    Filed: May 23, 2012
    Date of Patent: August 11, 2020
    Assignees: TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gGmbH, BioNTech RNA Pharmaceuticals GmbH
    Inventors: Ugur Sahin, Sebastian Kreiter, Mustafa Diken, Jan Diekmann, Michael Koslowski, Cedrik Britten, John Christopher Castle, Martin Lower, Bernhard Renard, Tana Omokoko, Johannes Hendrikus De Graaf
  • Method and kit for determining whether a subject shows an immune response
    Patent number: 10550430
    Abstract: The present invention relates to a kit and a method for determining whether a subject shows an immune response against an antigen.
    Type: Grant
    Filed: October 24, 2014
    Date of Patent: February 4, 2020
    Assignees: BIONTECH DIAGNOSTICS GMBH, TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG—UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH
    Inventors: Ugur Sahin, Michael Schäfer, Marta Magdalena Faryna, Tana Omokoko, Lisa Hebich, Petra Simon, Annett Reichardt, Özlem Öz
  • CLAUDIN-6-SPECIFIC IMMUNORECEPTORS AND T CELL EPITOPES
    Publication number: 20190389920
    Abstract: The present invention provides Claudin-6-specific immunoreceptors (T cell receptors and artificial T cell receptors (chimeric antigen receptors; CARs)) and T cell epitopes which are useful for immunotherapy.
    Type: Application
    Filed: June 18, 2019
    Publication date: December 26, 2019
    Inventors: Ugur SAHIN, Özlem TÜRECI, Petra SIMON, Tana OMOKOKO, Holger HOFF, Ralf-Holger VOSS, Andrea BREITKREUZ, Kathleen HOBOHM, Karolina Anna MROZ
  • Claudin-6-specific immunoreceptors and T cell epitopes
    Patent number: 10370423
    Abstract: The present invention provides Claudin-6-specific immunoreceptors (T cell receptors and artificial T cell receptors (chimeric antigen receptors; CARs)) and T cell epitopes which are useful for immunotherapy.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: August 6, 2019
    Assignees: Biotech Cell & Gene thrapies GMBH, Tron—Translationale Onkologie Ander Universitata tsmedizin Der Johannes Gutenberg-Universitat Main, Ganymed Pharmceuticals AG
    Inventors: Ugur Sahin, Özlem Türeci, Petra Simon, Tana Omokoko, Holger Hoff, Ralf-Holger Voss, Andrea Breitkreuz, Kathleen Hobohm, Karolina Anna Mroz
  • ANTIGEN-SPECIFIC T CELL RECEPTORS AND T CELL EPITOPES
    Publication number: 20190060430
    Abstract: The present invention relates to efficient methods for providing antigen-specific lymphoid cells. These lymphoid cells may be used to provide antigen specific T cell receptors having a defined MHC restriction and to identify immunologically relevant T cell epitopes. Furthermore, the present invention relates to antigen-specific T cell receptors and T cell epitopes and their use in immunotherapy.
    Type: Application
    Filed: September 4, 2018
    Publication date: February 28, 2019
    Applicants: BioNTech Cell & Gene Therapies GmbH
    Inventors: Ugur Sahin, Ozlem Tureci, Petra Simon, Tana Omokoko
  • Antigen-specific T cell receptors and T cell epitopes
    Patent number: 10117918
    Abstract: The present invention relates to efficient methods for providing antigen-specific lymphoid cells. These lymphoid cells may be used to provide antigen specific T cell receptors having a defined MHC restriction and to identify immunologically relevant T cell epitopes. Furthermore, the present invention relates to antigen-specific T cell receptors and T cell epitopes and their use in immunotherapy.
    Type: Grant
    Filed: December 28, 2016
    Date of Patent: November 6, 2018
    Assignees: BioNTech Cell & Gene Therapies GmbH, Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz Gemeinnutzige Gmbh
    Inventors: Ugur Sahin, Ozlem Tureci, Petra Simon, Tana Omokoko
  • CLAUDIN-18.2-SPECIFIC IMMUNORECEPTORS AND T CELL EPITOPES
    Publication number: 20180282389
    Abstract: The present invention provides Claudin-18.2-specific immunoreceptors (T cell receptors and artificial T cell receptors (chimeric antigen receptors; CARs)) and T cell epitopes which are useful for immunotherapy.
    Type: Application
    Filed: May 9, 2016
    Publication date: October 4, 2018
    Inventors: Ugur SAHIN, Ozlem TÜRECI, Petra SIMON, Tana OMOKOKO, Andrea BREITKREUZ, Karolina Anna MROZ, Lisa HEBICH
  • Antigen-Specific T Cell Receptors and T Cell Epitopes
    Publication number: 20170112911
    Abstract: The present invention relates to efficient methods for providing antigen-specific lymphoid cells. These lymphoid cells may be used to provide antigen specific T cell receptors having a defined MHC restriction and to identify immunologically relevant T cell epitopes. Furthermore, the present invention relates to antigen-specific T cell receptors and T cell epitopes and their use in immunotherapy.
    Type: Application
    Filed: December 28, 2016
    Publication date: April 27, 2017
    Inventors: Ugur Sahin, Ozlem Tureci, Petra Simon, Tana Omokoko
  • Antigen-specific T cell receptors and T cell epitopes
    Patent number: 9586997
    Abstract: The present invention relates to efficient methods for providing antigen-specific lymphoid cells. These lymphoid cells may be used to provide antigen specific T cell receptors having a defined MHC restriction and to identify immunologically relevant T cell epitopes. Furthermore, the present invention relates to antigen-specific T cell receptors and T cell epitopes and their use in immunotherapy.
    Type: Grant
    Filed: September 19, 2011
    Date of Patent: March 7, 2017
    Assignees: BioNtech Cell & Gene Therapies GmbH, Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz gemeinnutzige GmbH
    Inventors: Ugur Sahin, Ozlem Tureci, Petra Simon, Tana Omokoko
  • CLAUDIN-6-SPECIFIC IMMUNORECEPTORS AND T CELL EPITOPES
    Publication number: 20170015720
    Abstract: The present invention provides Claudin-6-specific immunoreceptors (T cell receptors and artificial T cell receptors (chimeric antigen receptors; CARs)) and T cell epitopes which are useful for immunotherapy.
    Type: Application
    Filed: March 30, 2015
    Publication date: January 19, 2017
    Applicants: Biontech Cell & Gene thrapies GMBH, Tron - Translationale Onkologie Ander Universitata tsmedizin Der Johannes Gutenberg-Universitat Main, Univeritatsmedizin der Johannes Gutenberg-, Ganymed Pharmceuticals AG
    Inventors: Ugur SAHIN, Özlem TÜRECI, Petra SIMON, Tana OMOKOKO, Holger HOFF, Ralf-Holger VOSS, Andrea BREITKREUZ, Kathleen HOBOHM, Karolina, Anna , MROZ